Pharma Insight ApS: Financial statements 2022
CVR: 40637117
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Pharma Insight ApS (CVR 40637117) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -27,014 and a net result of DKK -26,615 compared with DKK 47,936 the year before. Equity in the 2022 report amounted to DKK 146,202. The solvency ratio was 93.8%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -27,014
- Profit/Loss
- DKK -26,615
- Equity
- DKK 146,202
- Total Assets
- DKK 155,811
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -27 t. | -27 t. | 146 t. | 1 |
| 2021 | - | 725 t. | 48 t. | 273 t. | 1 |
Official annual report
Keep an eye on Pharma Insight ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Pharma Insight ApS has published its annual report for 2021. Gross profit came to DKK 725,062, and the net result was DKK 47,936.
About Pharma Insight ApS
Pharma Insight ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Marianne Kock and Peter Kock. The company is owned by Peter Kock Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 342,207 and a net result of DKK 265,159 compared with DKK 117,750 the year before. Equity in the 2025 report amounted to DKK 340,254.